Obesity Management
26 articles on Obesity Management, written by Shotlee and medically reviewed for clinical accuracy.
Beyond Willpower: Understanding Obesity's Metabolic Roots
Obesity is a complex, multi-organ disease, not a failure of willpower. This article delves into its metabolic underpinnings and outlines a practical approach to management, including modern medications and lifestyle adjustments.
7 min read
Survodutide Shines: Dual GLP-1/Glucagon Agonist Shows Major Weight Loss
Zealand Pharma and Boehringer Ingelheim announced breakthrough Phase 3 results for survodutide, a dual GLP-1 and glucagon receptor agonist, demonstrating significant weight reduction and metabolic improvements in adults with obesity or overweight.
7 min read
Duodenal Resurfacing: A New Hope Beyond GLP-1 Weight Loss?
The emergence of GLP-1 receptor agonists has revolutionized obesity treatment, but concerns about weight regain upon discontinuation are significant. New research on duodenal mucosal resurfacing suggests a potential breakthrough in maintaining weight loss long-term.
7 min read
Severe Obesity and Heart Failure: New Insights into Cardiac Muscle Recovery
A groundbreaking Johns Hopkins study reveals that severe obesity causes intrinsic cardiac muscle weakness, but weight loss can trigger significant recovery.
3 min read
Amazon Launches GLP-1 Weight Loss Program with Fast Access
Amazon is entering the GLP-1 weight loss market with a new program through One Medical and Amazon Pharmacy, promising fast, convenient access to treatments like Wegovy and Zepbound. With pricing as low as $25/month for insured patients and same-day delivery, it positions weight management as a chronic care solution. This could transform how patients access these popular medications.
5 min read
Novo Nordisk Bets on Clinical Depth vs Discounts for Semaglutide Generics in ...
After semaglutide's patent expired on March 20, over 40 Indian manufacturers launched 50+ generics, slashing prices up to 90%. Novo Nordisk, maker of Ozempic and Wegovy, is countering not with deep discounts but clinical data from 50+ trials and partnerships. Vikrant Shrotriya shares how this strategy aims to widen access while preserving quality.
5 min read
Semaglutide Prices Drop 70-90% in India After Generic Launches by Sun Pharma,...
Semaglutide prices in India have plummeted by up to 90% following the launch of over 15 generic versions just days after patent expiry. Major players like Sun Pharma, Zydus Lifesciences, Dr Reddy's, and Natco are offering affordable options for type 2 diabetes and obesity management. This shift promises greater access to this vital GLP-1 agonist therapy.
6 min read
GLP-1 Discontinuation: Mixed Weight Loss Results in Real-World Study
A large real-world study from Cleveland Clinic reveals mixed outcomes after GLP-1 discontinuation: 55% of obese patients regained weight, while 45% maintained or continued losing. Many switched to alternative treatments, highlighting the need for ongoing obesity care. This data underscores gaps in long-term management and the role of nutritional support.
5 min read
GLP-1 Persistence for Weight Loss Nearly Doubles in Recent Years
Persistence rates for GLP-1 medications like semaglutide and tirzepatide in patients without diabetes seeking weight loss have nearly doubled over the past five years, jumping from 33.2% in 2021 to 60.9% in mid-2024. New research highlights improved adherence, the role of drug switching, and factors like resolved supply shortages driving these gains. These trends offer hope for long-term obesity management.
5 min read
CDSCO Advisory Curbs Misleading Promotion of GLP-1 Obesity Drugs
India's CDSCO has issued a strict advisory against misleading promotions of prescription obesity drugs like GLP-1 receptor agonists. The regulator targets indirect ads, exaggerated claims, and efforts undermining lifestyle changes. This move reinforces ethical marketing and patient safety in obesity treatment.
4 min read
What Happens After Stopping GLP-1 Drugs Like Ozempic? UK Study Findings
A new Cambridge study reveals that after stopping GLP-1 drugs like Ozempic and Wegovy, patients regain nearly 60% of lost weight within a year, with appetite returning rapidly. Researchers modeled long-term trends showing about 75% regain over time, emphasizing the need for lifestyle support. This comprehensive guide breaks down the findings and what they mean for patients.
6 min read
Glenmark to Launch Affordable Semaglutide, Joining Indian Peers
Glenmark Pharmaceuticals is gearing up to launch affordable versions of semaglutide, the blockbuster GLP-1 drug for diabetes and obesity, later this month. This move intensifies competition among Indian drugmakers like Sun Pharma and Dr Reddy's following the March 21 patent expiry. With prices potentially half those of innovators, millions of patients stand to gain better access.
5 min read
Zydus Launches Semaglutide in Reusable Pen After Patent Expiry: Prices to Fall
Zydus Lifesciences is set to revolutionize semaglutide access in India with a reusable adjustable pen device after the patent expires on March 20. Brands like SEMAGLYN™, MASHEMA™, and ALTERMET™ promise easier dosing and lower prices around ₹3,500-4,000 per month. This move could expand GLP-1 therapy for Type 2 diabetes and obesity amid rising demand.
5 min read
GLP-1 RAs Reduce Food Noise by 46%, Emerging Evidence Shows
Emerging evidence suggests GLP-1 receptor agonists (GLP-1 RAs) not only aid weight loss but also significantly quiet 'food noise'—those persistent, distressing thoughts about food. In the US-based INFORM survey, 550 individuals using GLP-1s reported a 46% reduction in constant food thoughts, alongside mental health gains. This could redefine obesity management for better holistic outcomes.
6 min read
GLP-1 Drugs for Obesity: Why Treatment is Lifelong Like Oprah's Story
Oprah Winfrey shared on her podcast that stopping GLP-1 injections led to significant weight regain, sparking debate on obesity treatment. Expert insights reveal these drugs treat a chronic condition, not just temporary weight loss. Learn the science, risks, and how to approach long-term success.
4 min read
Calgary Doctor Claims Generic Ozempic and Wegovy Drugs May Cut Costs by One-Third
According to a Calgary doctor, affordable generic alternatives to drugs like Ozempic and Wegovy might reduce expenses by up to a third. The content explores regional approaches to obesity management in Canada, emphasizing the challenges of rewiring brain circuitry and the role of medications in promoting healthier eating habits.
1 min read
Must Ozempic Be Used Indefinitely After Starting? UK Surgeon Details Consequences of Discontinuing GLP-1 Medications
Ozempic, a GLP-1 agonist, has surged in popularity for rapid weight loss, mimicking natural hormones to curb hunger and aid glucose management. However, concerns arise about temporary effects and weight rebound upon cessation. Dr. Karan Rajan explains the implications, emphasizing lifestyle adjustments for sustainable health without perpetual medication reliance.
3 min read
What is 'Food Noise' and Why It's Gaining Attention with the Surge in GLP-1 Drugs?
Before starting Ozempic in spring 2023, Brenda Rogers hadn't recognized how 'food noise' drained her mental stamina. This term describes a constant preoccupation with food, tied to GLP-1 medications for diabetes and obesity. Experts explain its causes, how drugs alleviate it, and alternative approaches like therapy and diet adjustments.
4 min read
Weight Loss Drugs Cessation Linked to Regain and Cardiac Hazards
A comprehensive analysis published in The BMJ reveals that discontinuing weight loss drugs leads to an average monthly regain of 0.4 kg, with full weight and cardiometabolic risks returning within two years. This regain occurs nearly four times faster than after dietary and lifestyle interventions, raising questions about the drugs' long-term effectiveness. Experts emphasize combining medications with healthy habits for sustainable obesity control.
3 min read
6 Facts to Understand About the New GLP-1 Weight Loss Pill
The introduction of a GLP-1 pill for weight loss marks a significant advancement in obesity treatment, offering an oral alternative to injections like Wegovy. Experts highlight its potential for broader access, though it shares similar expenses, adverse effects, and the necessity for a healthy lifestyle. Key details cover efficacy, timelines for results, pricing, side effects, dosing requirements, and upcoming options.
4 min read
Wegovy Oral Tablet Lands in US, Delivering Innovative Pill-Based Solution for Weight Management
The United States now offers an additional avenue for weight reduction as Novo Nordisk introduces its Wegovy oral medication across the country. This daily tablet, featuring semaglutide, represents the initial and sole GLP-1 pill for adults, simplifying obesity management without injections. Clinical studies indicate notable weight loss, though side effects may occur.
2 min read
From Shots to Subscriptions: The Rebranding of GLP-1 Drugs
Pharmaceutical giants like Novo Nordisk and Eli Lilly are transforming GLP-1 drugs into everyday consumer products, introducing oral versions and emphasizing cash-pay models. This shift, driven by telehealth and apps, aims to make weight loss as accessible as online shopping, while experts raise concerns about medical oversight.
5 min read
A GLP-1 Weight Loss Pill Approaches. Here's Its Comparison to Injections
Injectable GLP-1 medications have revolutionized obesity management, and now an oral option is emerging. The FDA has approved a pill version of semaglutide for weight loss and cardiovascular risk reduction.
1 min read
Uzbekistan Approves Initial Local Version of Danish Obesity Medication Ozempic
Uzbekistan has registered Semavik, a Russian-produced medication containing semaglutide, designed to treat type 2 diabetes and obesity. This marks the first local equivalent of the Danish drug Ozempic in the country. The approval addresses the increasing prevalence of metabolic diseases.
1 min read
Novo Nordisk India's Vikrant Shrotriya on Ensuring Ozempic Supply
Vikrant Shrotriya of Novo Nordisk India details Ozempic's launch in India, emphasizing stable supply and accessibility. He addresses patent expiry and competition, focusing on broader patient access and combating obesity.
6 min read
GLP-1 Breakthrough: Mazdutide Outperforms Semaglutide for Weight Loss & Diabetes
New research shows that Mazdutide may be superior to Semaglutide (Ozempic/Wegovy) for weight loss and improved blood sugar control. Learn about this exciting development and what it means for the future of diabetes and weight management.
3 min read